Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
MRVI 
Maravai Lifesciences Holdings Inc (MRVI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: MRVI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
13 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $5.06
1 Year Target Price $5.06
| 5 | Strong Buy |
| 1 | Buy |
| 7 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -35.04% | Avg. Invested days 17 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 880.48M USD | Price to earnings Ratio - | 1Y Target Price 5.06 |
Price to earnings Ratio - | 1Y Target Price 5.06 | ||
Volume (30-day avg) 13 | Beta 0.25 | 52 Weeks Range 1.67 - 10.03 | Updated Date 07/1/2025 |
52 Weeks Range 1.67 - 10.03 | Updated Date 07/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.17 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -67.28% | Operating Margin (TTM) -78.39% |
Management Effectiveness
Return on Assets (TTM) -4.64% | Return on Equity (TTM) -44.32% |
Valuation
Trailing PE - | Forward PE 370.37 | Enterprise Value 432547803 | Price to Sales(TTM) 3.64 |
Enterprise Value 432547803 | Price to Sales(TTM) 3.64 | ||
Enterprise Value to Revenue 1.79 | Enterprise Value to EBITDA 1.77 | Shares Outstanding 143975008 | Shares Floating 92403435 |
Shares Outstanding 143975008 | Shares Floating 92403435 | ||
Percent Insiders 9.93 | Percent Institutions 89.93 |
Analyst Ratings
Rating 3 | Target Price 5.06 | Buy 1 | Strong Buy 5 |
Buy 1 | Strong Buy 5 | ||
Hold 7 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Maravai Lifesciences Holdings Inc
Company Overview
History and Background
Maravai Lifesciences was founded in 2014. It has grown through strategic acquisitions and organic growth, focusing on providing critical products and services to enable drug development programs.
Core Business Areas
- Nucleic Acid Production: Produces modified nucleic acids used in diagnostics, vaccines, and therapeutics. These include CleanCap mRNA capping technology.
- Biologics Safety Testing: Offers testing solutions to ensure the safety and purity of biologics, including antibodies and vaccines.
- Protein Production: Specializes in protein production and custom antibody development.
Leadership and Structure
The company has a CEO-led structure with a board of directors overseeing strategic direction. Key leaders focus on different business segments and research & development.
Top Products and Market Share
Key Offerings
- CleanCap mRNA Capping Technology: This technology is used to cap mRNA molecules, improving their stability and translation efficiency. It is a key component in mRNA vaccine and therapy development. There is no reliable single market share data. Revenue from this product can vary year to year. Competitors include Trilink Biotechnologies, Jena Bioscience, and others with mRNA capping technologies.
- GMP-grade plasmid DNA: Used in cell and gene therapy production. GMP-grade plasmid DNA is essential to ensure product safety and efficacy. No reliable market share data. Key competitors are Aldevron, Charles River Laboratories.
Market Dynamics
Industry Overview
The life sciences industry is experiencing rapid growth, driven by advances in genomics, proteomics, and personalized medicine. The COVID-19 pandemic accelerated the development of mRNA vaccines and therapeutics, increasing demand for specialized services and products.
Positioning
Maravai Lifesciences is positioned as a key enabler of drug development, providing critical components and services to pharmaceutical and biotech companies. Its competitive advantage lies in its specialized expertise and high-quality products.
Total Addressable Market (TAM)
The total addressable market for Maravai Lifesciences' products and services is estimated to be in the billions of dollars, influenced by bioproduction, vaccines, and mRNA-based therapies. Maravai Lifesciences is positioned to capture a substantial portion of this market by supplying to key players in the biotechnology and pharmaceutical industries.
Upturn SWOT Analysis
Strengths
- Strong market position in mRNA capping technology
- Diversified product portfolio
- Expertise in biologics safety testing
- Established relationships with leading pharmaceutical companies
Weaknesses
- Dependence on the growth of the mRNA therapeutics market
- Competition from larger, more diversified companies
- Fluctuations in demand due to pandemic effects
- Risk associated with the rapidly evolving biotech industry
Opportunities
- Expansion into new therapeutic areas
- Development of new technologies and services
- Strategic acquisitions to broaden product offerings
- Increased demand for biologics safety testing
Threats
- Increased competition from new entrants
- Regulatory changes impacting the biologics industry
- Economic downturn affecting research and development spending
- Supply chain disruptions
Competitors and Market Share
Key Competitors
- DHR
- TMO
- VRSK
Competitive Landscape
Maravai faces competition from larger, more diversified players, but its specialized expertise and innovative technologies provide a competitive edge.
Major Acquisitions
Alphazyme
- Year: 2021
- Acquisition Price (USD millions): 175
- Strategic Rationale: Expanded Maravai's enzymatic capabilities to further support bioprocessing and diagnostics.
Growth Trajectory and Initiatives
Historical Growth: Historical growth was significant, driven by the mRNA vaccine market. Future projections suggest moderated, but steady, growth.
Future Projections: Future growth projections depend on the continued expansion of mRNA therapeutics and overall growth in biologics testing.
Recent Initiatives: Recent initiatives include expanding production capacity and investing in new technologies.
Summary
Maravai Lifesciences is a key player in the life sciences industry, particularly in providing critical components for mRNA-based therapies and biologics safety testing. The company has experienced strong growth due to the rise of mRNA vaccines, but faces increasing competition. While its specialized expertise is an advantage, Maravai needs to diversify its revenue streams and navigate the evolving biotech landscape. Ongoing investments into research and development will be crucial for future success and shareholder value.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Industry News
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market data is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Maravai Lifesciences Holdings Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2020-11-20 | CEO & Director Mr. Bernd Brust | ||
Sector Healthcare | Industry Biotechnology | Full time employees 580 | Website https://www.maravai.com |
Full time employees 580 | Website https://www.maravai.com | ||
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, and oligonucleotide therapy, as well as molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, CleanCap capping technology-based oligonucleotide building blocks, and custom enzyme development and manufacturing; and research products for labeling and detecting proteins in cells and tissue samples. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, and antibody-based products to detect impurities during the production of biopharmaceutical products. It serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. Maravai LifeSciences Holdings, Inc. was founded in 2014 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.